定义与促进儿科肺健康:开发肺健康生物标志物
本文总结了2021年美国国家心肺血液研究所资助的「定义与促进儿科肺健康」研讨会上关于肺健康生物标志物的会议内容。会议讨论了基因检测、脉搏血氧测定、呼出气一氧化氮及与儿童肺疾病相关的新型生物标志物,旨在在呼吸疾病导致生命或肺功能丧失之前进行检测和治疗。
要点
- 儿童遗传性和/或获得性呼吸疾病常在青春期和成年期出现肺功能下降。
- 基因评估、低成本诊断和微创新型生物标志物正在发展中。
- 会议讨论了基因检测、脉搏血氧测定、呼出气一氧化氮和新型生物标志物。
核心结论
- 需要更好的机制来识别和评估呼吸疾病进展,以便在肺功能丧失前检测和治疗。
研究设计与样本
- 本文总结了2021年美国国家心肺血液研究所资助的「定义与促进儿科肺健康」研讨会上关于开发肺健康生物标志物的会议内容。
主要发现
- 会议讨论了基因检测、脉搏血氧测定、呼出气一氧化氮及与儿童肺疾病相关的新型生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with inherited and/or acquired respiratory disorders often arrive in adolescence and adulthood with diminished lung function that might have been detected and prevented had better mechanisms been available to identify and to assess progression of disease. Fortunately, advances in genetic assessments, low-cost diagnostics, and minimally- invasive novel biomarkers are being developed to detect and to treat respiratory diseases before they give rise to loss of life or lung function. This paper summarizes the Developing Biomarkers for Pulmonary Health sessions of the National Heart, Lung, and Blood Institute- sponsored 2021 Defining and Promoting Pediatric Pulmonary Health workshop. These sessions discussed genetic testing, pulse oximetry, exhaled nitric oxide, and novel biomarkers related to childhood lung diseases.
引用
- Davis MD, Zein JG, Carraro S, et al. Defining and Promoting Pediatric Pulmonary Health: Developing Biomarkers for Pulmonary Health. Pediatrics. 2023. PMID: 37656025. doi:10.1542/peds.2023-062292C
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。